Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

IRDye800CW-nimotuzumab

A fluorescence imaging and contrast agent and immunoconjugate comprised of nimotuzumab, a humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR), conjugated to the near-infrared (NIR) fluorescent dye IRDye 800CW, with potential imaging use. Upon administration of IRDye800CW-nimotuzumab, the nimotuzumab moiety targets and binds to the extracellular domain of EGFR. Upon binding, IRDye 800 may be detected using NIR imaging, which facilitates the visualization and detection of EGFR-expressing tumor cells. EGFR is a receptor tyrosine kinase that may be overexpressed on the cell surfaces of various tumor types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:IRDye800CW-labeled nimotuzumab
nimotuzumab-IRDye800CW
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search